The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase
Cell and gene therapy clinical trials in development worldwide 2019, by trial phase
As of November 2019, 55 percent of clinical trials in cell and gene therapy development were in phase two, and 30 percent were in phase one of clinical trials. This statistic shows the proportion of clinical trials for cell and gene therapies worldwide as of late-2019, by clinical trial phase.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Indications in clinical trials for cell and gene therapies worldwide 2022
- Basic Statistic Key indications in oncology pipeline worldwide 2023
- Basic Statistic Mechanism of action in oncology pipeline worldwide 2023
- Premium Statistic Mechanism of action in obesity R&D pipeline worldwide 2024
- Basic Statistic Orphan and non-orphan drugs in the pipeline worldwide 2021
- Basic Statistic U.S. and Europe's selected anti-CD19 Car-T therapy sales forecast 2024
- Basic Statistic Global biologics discovery market worldwide by phase 2016-2025
- Premium Statistic Amgen research and development expenditure 2006-2025
- Premium Statistic Value of top U.S. biotech IPOs 2024
- Basic Statistic WAC and ASP of Neulasta (pegfilgrastim) biosimilars in the U.S. 2022
About the region
10
- Basic Statistic Clinical trials initiated worldwide 2018-2024, by trial phase
- Premium Statistic Clinical trials initiated worldwide 2018-2024
- Basic Statistic Average number of site per drug trial started worldwide 2015-2020, by phase
- Basic Statistic Key categories in orphan drug pipeline worldwide 2022
- Basic Statistic Average total number of site per drug trial started worldwide 2012-2023
- Basic Statistic Drugs in R&D pipeline worldwide 2025-2026, by phase of development
- Premium Statistic Average value of biopharma M&A deals worldwide 2010-2019, by industry
- Basic Statistic Alzheimer’s disease therapies in phase II development 2025, by type
- Basic Statistic Alzheimer’s disease drugs in trial phase II by mechanism of action 2025
- Basic Statistic Number of new medicines in R&D pipeline worldwide 2021-2023, by phase
Selected statistics
10
- Premium Statistic Number of active trials for cell and gene therapies worldwide 2022 by trial phase
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Premium Statistic Number of active trials for cell and gene therapies 2022, by region
- Basic Statistic Number of cell and gene therapy deals worldwide 2016-2020, by type
- Premium Statistic Top global biotech companies — R&D expenditure 2024
- Basic Statistic Comparison of ASP Herceptin vs biosimilars in the U.S. Q1 2026
- Premium Statistic Number of medical biotechnology companies in Germany 2010-2024
- Premium Statistic Merck & Co.'s main-selling drugs 2025
- Premium Statistic Major global biotech companies' selection based on market cap 2026
- Basic Statistic Market cap of gene and cell therapy companies 2026
Other regions
10
- Premium Statistic Size of U.S. CRO market 2024 vs. 2031
- Premium Statistic Revenue breakdown of the major CROs in China 2019, by segment
- Basic Statistic Total per-study costs by clinical trial phase and therapeutic area
- Premium Statistic Top companies based on CAR-T cancer therapy patents 2010-2021
- Basic Statistic Value of M&As in the U.S. healthcare and life sciences sector 2009-2021
- Premium Statistic Per day clinical trial mean direct cost by phase
- Basic Statistic Number of NAS approved by Health Canada 2014-2021
- Premium Statistic Time from R&D start to approval of select cancer drugs 2017
- Premium Statistic Novel pain drug clinical trials success rates U.S. 2006-2015, by phase
- Premium Statistic Total R&D costs of select cancer drugs 2017
Related statistics
10
- Premium Statistic Share of biopharmaceutical companies with 100% in-house manufacturing 2022
- Premium Statistic Expected short-term capacity constraints among biopharma manufacturers 2022
- Basic Statistic Clinical drug trials started worldwide 2018-2023, by key therapeutic area
- Basic Statistic Number of active trials in Alzheimer's Disease pipeline 2022, by product type
- Premium Statistic Top R&D partnerships on biopharma therapeutics worldwide in 2020 by deal value
- Basic Statistic Key technologies in Alzheimer's Disease clinical trials 2021
- Basic Statistic mRNA therapeutic vaccine clinical trials worldwide by cancer 2022-2024
- Premium Statistic Outsourced research penetration in pharmaceutical industry worldwide 2011-2020
- Premium Statistic Preclinical CRO market share worldwide by company 2016
- Premium Statistic Top 10 global pharmaceutical companies by revenue 2025
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Deloitte. (January 11, 2020). Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 30, 2026, from /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/
Deloitte. "Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase." Chart. January 11, 2020. ÌÇÐÄÆƽâ°æ. Accessed July 30, 2026. /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/
Deloitte. (2020). Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 30, 2026. /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/
Deloitte. "Proportion of Clinical Trials for Cell and Gene Therapies Worldwide as of 2019, by Clinical Trial Phase." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 11 Jan 2020, /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/
Deloitte, Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase ÌÇÐÄÆƽâ°æ, /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/ (last visited July 30, 2026)
Proportion of clinical trials for cell and gene therapies worldwide as of 2019, by clinical trial phase [Graph], Deloitte, January 11, 2020. [Online]. Available: /statistics/1098060/cell-and-gene-therapy-clinical-trials-by-phase-worldwide/
Advertisement